Multiple ‘Centers of Excellence’ At US FDA Could Create Review Inefficiencies – Jenkins
FDA’s outgoing head of new drug review cautions against duplicating Oncology ‘Center of Excellence’ model across multiple therapeutic areas, advocating for a more ‘balanced portfolio’ in structuring review operations; other topics during podcast interview include Jenkins’ future plans in drug regulation and one major safety decision that turned out differently than expected.
You may also be interested in...
Commissioner Gottlieb says new centers would follow template of Oncology Center of Excellence.
While OCE has a lofty status, it has yet to gain a large cadre of staff.
US FDA commissioner nominee might employ modular specialists to work with review divisions on issues related to gene therapies, molecularly-targeted drugs, adaptive clinical trial designs, or other complex issues.